Entera Bio Ltd. (ENTX) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing first-in-class oral tablet formats of peptides using its proprietary N-Tab™ platform. The company is incorporated in Israel and listed on the Nasdaq Capital Market. Its primary focus is on underserved chronic conditions, including osteoporosis (EB613), hypoparathyroidism (EB612), and obesity/metabolic disorders (Oral OXM in collaboration with OPKO Health).
Key Financial Metrics
| Metric (in thousands, except per share) | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 |
|---|---|---|
| Revenues | $0 | $42 |
| Operating Expenses | $3,256 | $8,487 |
| Net Loss | $3,200 | $8,423 |
| Loss Per Share (Basic & Diluted) | $0.07 | $0.18 |
| Cash and Cash Equivalents | $8,574 | $8,574 |
| Restricted Cash | $8,028 | $8,028 |
| Total Cash & Restricted Cash | $16,602 | $16,602 |
| Accumulated Deficit | $(122,350) | $(122,350) |
Note: The filing does not provide specific margin percentages as the company has no significant revenue. Debt is minimal, consisting primarily of operating lease liabilities ($211k total).
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $0 for the three months ended September 30, 2025, compared to $42,000 in the same period in 2024. This is due to the completion of a research services agreement in Q1 2025.
- Increased Operating Loss: Net loss increased to $3.2 million for the quarter (from $3.0 million in Q3 2024) and $8.4 million for the nine-month period (from $7.2 million in the prior year). The increase is driven by higher R&D expenses related to regulatory filings for the EB613 Phase 3 program and the new OPKO collaboration.
- Liquidity Position: Total cash and restricted cash increased significantly to $16.6 million from $8.7 million at year-end 2024. This increase is primarily due to $8.0 million in restricted cash deposited into an escrow account to fund obligations under the new OPKO collaboration agreement.
- Equity Issuance: The company issued 3,685,226 shares to OPKO Health for $8.0 million and raised approximately $6.1 million net through its At-The-Market (ATM) program during the nine-month period.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management believes current cash resources (excluding the restricted OPKO funds) are sufficient to fund operations through the middle of the third quarter of 2026. This runway covers ongoing operations, Phase 1 studies for next-gen EB613 and Oral OXM, and preparation for the EB613 Phase 3 program. However, the company explicitly states it does not have sufficient capital to commence the full Phase 3 program for EB613 without additional funding.
Key Developments:
- EB613 (Osteoporosis): FDA agreed that a single 24-month Phase 3 study with Total Hip BMD as the primary endpoint can support an NDA filing. Post-hoc data presented in late 2025 showed significant increases in bone parameters.
- OPKO Collaboration: A new agreement was signed in March 2025 to develop an oral dual GLP-1/Glucagon agonist (OXM) for obesity. OPKO holds 60% of proceeds and funding responsibility; Entera holds 40%.
Risks and Contingencies:
- Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern due to recurring losses and the need for additional capital to fund Phase 3 trials.
- Geopolitical Risk: The company highlights risks associated with the ongoing conflict in Israel (involving Hamas, Hezbollah, and Iran). While a ceasefire was reached in October 2025, the company notes that escalation could disrupt operations, though current impact is deemed immaterial.
- Regulatory Uncertainty: Success depends on FDA approval of BMD as a surrogate endpoint and the successful execution of clinical trials.
Investor Verification Checklist
- Capital Runway: Verify the specific timeline for the "middle of Q3 2026" runway and the estimated cost to launch the EB613 Phase 3 trial.
- Restricted Cash Usage: Confirm the terms of the escrow agreement with OPKO and the conditions under which the $8.0 million restricted cash can be released or utilized.
- Phase 3 Readiness: Assess the status of the FDA Type A meeting outcomes and the timeline for initiating the pivotal Phase 3 study for EB613.
- Geopolitical Exposure: Monitor the stability of the ceasefire in the Middle East and its potential impact on the company's Israeli-based research personnel and facilities.
- Dilution Risk: Review the remaining capacity under the refreshed ATM program (30 million shares) and the potential for further equity dilution to fund future operations.